EUVIMEDEUVIMED entdecken
Crossref

Exploring the Bioactive Constituents and Therapeutic Mechanisms of Sanhuang Xiexin Decoction in Hypercholesterolemia Treatment Using UHPLC‐Q‐Orbitrap‐MS/MS Integrated With Metabolomics and Network Pharmacology

Yatong Zhu iD, Xinlei Yang, Furong Wang, Mengting Zhao, Junli Hong iD, Jun Zhang, Lin Wang iD

Rapid Communications in Mass Spectrometry · 2025

DOI: 10.1002/rcm.10035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Yatong Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Hypercholesterolemia. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province, Graduate Innovation Foundation of Yantai University, Jiangsu Innovation and Entrepreneurship Training Program for College Students.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rational Sanhuang Xiexin Decoction (SHD), a traditional Chinese medicine, has been used widely in East Asian Countries for hundreds of years and recent studies have implied its lipid‐lowering and cardiovascular protective effects. However, the active components and potential mechanism of SHD in treating hypercholesterolemia (HC) remain unclear.

Methods

UHPLC‐Q‐Orbitrap‐MS/MS was used to annotate the components in SHD, and then, the efficacy of SHD in alleviating HC was demonstrated in vitro and in vivo . Subsequently, metabolomics by UHPLC‐Q‐Orbitrap‐MS/MS was employed to identify discriminative metabolites and metabolic pathways involved in SHD against HC. Network pharmacology was applied to explore the potential bioactive components. Then, the integrated approach was proposed to elucidate the possible targets and mechanisms. Finally, molecular docking was operated to validate the potential targets and bioactive components.

Results

A total of 180 chemical components were identified in SHD, and 18 prototype components were confirmed in vivo . Metabolomics study revealed 12 metabolites, and five metabolic pathways were associated with the efficacy of SHD. Network pharmacology analysis further identified 18 active compounds and 107 targets. Finally, the integrated approach suggested that SHD exerts its protective effects against HC by modulating purine and glycerophospholipid metabolism through the regulation of key targets, including phosphodiesterase 5 (PDE5), acetylcholinesterase (ACHE), phospholipase A2 group VII (PLA2G7), and xanthine dehydrogenase (XDH).

Conclusion

SHD exerts its therapeutic effects on HC through multiple targets and multiple mechanisms. This study lays the groundwork for the clinical application of SHD in the treatment of HC and paves the way for further exploration of its underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalHypercholesterolemiaMetabolomicsAnimalsChromatography, High Pressure LiquidTandem Mass SpectrometryNetwork PharmacologyMaleMolecular Docking SimulationMiceMetabolic Networks and PathwaysHumans

Stichwörter der Autor:innen

Sanhuang Xiexin DecoctionUHPLC‐Q‐Orbitrap‐MS/MSmetabolomicsnetwork pharmacology

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
  • School of Pharmacy, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Yatong Zhu, Junli Hong, Lin Wang

Förderung

  • Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province
  • Graduate Innovation Foundation of Yantai University
  • Jiangsu Innovation and Entrepreneurship Training Program for College Students

Zitieren

APA

Zhu, Y., Yang, X., Wang, F., Zhao, M., Hong, J., Zhang, J., & Wang, L. (2025). Exploring the Bioactive Constituents and Therapeutic Mechanisms of Sanhuang Xiexin Decoction in Hypercholesterolemia Treatment Using UHPLC‐Q‐Orbitrap‐MS/MS Integrated With Metabolomics and Network Pharmacology. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10035

Vancouver

Zhu Y, Yang X, Wang F, Zhao M, Hong J, Zhang J, et al. Exploring the Bioactive Constituents and Therapeutic Mechanisms of Sanhuang Xiexin Decoction in Hypercholesterolemia Treatment Using UHPLC‐Q‐Orbitrap‐MS/MS Integrated With Metabolomics and Network Pharmacology. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10035

BibTeX
@article{Zhu2025,
  author = {Zhu, Yatong and Yang, Xinlei and Wang, Furong and Zhao, Mengting and Hong, Junli and Zhang, Jun and Wang, Lin},
  title = {Exploring the Bioactive Constituents and Therapeutic Mechanisms of Sanhuang Xiexin Decoction in Hypercholesterolemia Treatment Using UHPLC‐Q‐Orbitrap‐MS/MS Integrated With Metabolomics and Network Pharmacology},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2025},
  doi = {10.1002/rcm.10035}
}
Kostenlos starten →